Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 2, 2005 - Issue 1
Submit an article Journal homepage
286
Views
32
CrossRef citations to date
0
Altmetric
Review

Propellant-driven metered-dose inhalers for pulmonary drug delivery

Hugh DC Smyth University of North Carolina at Chapel Hill, School of Pharmacy, NC 27599, USA
Pages 53-74 | Published online: 22 Apr 2005

Bibliography

  • Adjei A, Gupta P (Ed.), Marcel Dekker, New York (1997): 185–229.
  • FINK JB: Metered-dose inhalers, dry powder inhalers, and transitions. Respir. Care (2000) 45(6):623–635.
  • COLTHORPE P: Industry experiences of the HFA transition. Drug Del. Syst. (2003) 3(9):41–43.
  • WINNIPS C, KELLER M: The role of pMDIs in pulmonary drug delivery. Innov. Pharm. Tech. (2000) 00(6):72–75.
  • BOULET LP: The ozone layer and metered dose inhalers. Can. Respir. J. (1998) 5(3):176–179.
  • TIWARI D, GOLDMAN D, DIXIT S, MALICK WA, MADAN PL: Compatibility evaluation of metered-dose inhaler valve elastomers with tetrafluoroethane (P134a), a non-CFC propellant. Drug Dev. Ind. Pharm. (1998) 24(4):345–352.
  • CUMMINGS RH: Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performance. J. Allergy Clin. Imm. (1999) 104(6):5230–5235.
  • BERRY J, KLINE L, NAINI V, CHAUDHRY S, HART J, SEQUEIRA J: Influence of the valve lubricant on the aerodynamic particle size of a metered dose inhaler. Drug Dev. Ind. Pharm. (2004) 30(3):267–275.
  • POLLI GP, GRIM WM, BACHER FA, YUNKER MH: Influence of formulation on aerosol particle size. J. Pharm. Sci. (1969) 58(Apr):484–486.
  • LEWIS D, JOHNSON S, MEAKIN B et al.: Effects of actuator orifice diameter on beclomethasone dipropionate delivery from a pMDI HFA solution formulation. Proceedings of Respiratory Drug Delivery VI Conference. (1998). 1: 363–364.
  • RANUCCI JA, COOPER D, SETHACHUTKUL K: Effect of actuator design on metered-dose inhaler plume-particle size. Pharm. Tech. (1992) 16:90–92.
  • BRAMBILLA G, GANDERTON D, GARZIA R, LEWIS D, MEAKIN B, VENTURA P: Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int. J. Pharm. (1999) 186(1):53–61.
  • WARREN SJ, FARR SJ: Formulation of solution metered dose inhalers and comparison with aerosols emitted from conventional suspension systems. Int. J. Pharm. (1995) 124(2):195–203.
  • SMYTH HDC: The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv. Drug Del. Rev. (2003) 55(7):807–828.
  • STEIN SW, MYRDAL PB: A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions. J. Pharm. (2004) 93(8):2158–2175.
  • U5P24. Aerosols, metered dose inhalers, and dry powder inhalers. The United States Pharmacopeia and National Formulary (2000):1895–1912.
  • CLARK AR: Metered atomization for respiratory drug delivery [Ph.D.]: Loughborough University of Technology, U.K. (1991).
  • DUNBAR CA, WATKINS AP, MILLER JF: Theoretical investigation of the spray from a pressurized metered-dose inhaler. Atomization Sprays (1997) 7(4):417–436.
  • DUNBAR CA, WATKINS AP, MILLER JF: An experimental investigation of the spray issued from a pMDI using laser diagnostic techniques. J. Aerosol. Med. (1997) 10(4):351–368.
  • FINLAY WH: The mechanics of inhaled pharmaceutical aerosols. Academic Press: London (2001).
  • SMYTH HDC, GALLION JA, GROVE JA, BRACE G, HICKEY AJ: Correlation of spray patterns with droplet size for pressurized metered dose inhalers. Paper presented at: Annual Meeting of American Association of Pharmaceutical Sciences. Toronto, Canada, Nov (2002).
  • CROMPTON GK: The adult patient's difficulties with inhalers. Lung (1990) 168(Suppl.):658–662.
  • WILKES W, FINK J, DHAND R: Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J. Aerosol. Med. (2001) 14(3):351–360.
  • BERG E, MADSEN J, BISGAARD H: In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur. Resp. J. (1998) 12(2):472–476.
  • SMYTH HDC, BECK VP, WILLIAMS D, HICKEY AJ: The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers. AAPS PharmSci Tech (2004) 5(1):Article 7.
  • JOHNSON DH, ROBART P: Inhaler technique of outpatients in the home. Respir. Care (2000) 45(10):1182–1187.
  • WILLIAMS RO, III, PATEL AM, BARRON MK, ROGERS TL: Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. Drug Dev. Ind. Pharm. (2001) 27(5):401–412.
  • AHRENS R, LUX C, BAHL T, HAN S: Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. J. Allergy Clin. Immunol (1995) 96(2):288–294.
  • MITCHELL JP, NAGEL MW, RAU JL: Performance of large-volume versus small-volume holding chambers with chlorofluorocarbon-albuterol and hydrofluoroalkane-albuterol sulphate. Respir. Care (1999) 44(1):38–44.
  • WILDHABER JH, JANSSENS HM, PIERART F, DORE ND, DEVADASON SG, LESOUEF PN: High-percentage lung delivery in children from detergent-treated spacers. Paediatric Pulmonology (2000) 29(5):389–393.
  • PEART J, BYRON PR: Electrostatic properties of metered dose inhalers. Inst. Phys. Conf Ser. (1999) 163(Electrostatics 1999):77–80.
  • WILDHABER JH, DEVADASON SG, HAYDEN MJ et al.: Electrostatic charge on a plastic spacer device influences the delivery of salbutamol. Eur. Respir. J. (1996) 9(9):1943–1946.
  • WILDHABER JH, DEVADASON SG, EBER E et al.: Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax (1996) 51(14985–988.
  • WILDHABER JH, HAYDEN MJ, DORE ND, DEVADASON SG, LESOUEF PN: Salbutamol delivery from a hydrofluoroalkane pressurized metered-dose inhaler in paediatric ventilator circuits: an in vitro study. Chest (1998) 113(1):186–191.
  • PIERART F, WILDHABER JH, VRANCKEN I, DEVADASON SG, LE SOUEF PN: Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur. Resp. J. (1999) 13(3):673–678.
  • ANHOJ J, BISGAARD H, LIPWORTH BJ: Effect of electrostatic charge in plastic spacers on the lung delivery of HFA-salbutamol in children. Br. J. Clin. Pharmacol (1999) 47(3):333–336.
  • DONNELL D: Inhaled corticosteroid delivery systems: clinical role of a breath-actuated device. Eur. Rev. Med. Pharmacol Sci. (2001) 5(1):7–16.
  • VERVAET C, BYRON PR: Drug-surfactant-propellant interactions in HFA-formulations. Int. J. Pharm. (1999) 186(1):13–30.
  • DICKINSON PA, SEVILLE PC, MCHALE H, PERKINS NC, TAYLOR G: An investigation of the solubility of various compounds in the hydrofluoroalkane propellants and possible model liquid propellants. J. Aerosol. Med. (2000) 13(3):179–186.
  • CLARK A: Pulmonary delivery technology: recent advantages and potential for the new mellenium. In: Pharmaceutical Inhalation Aerosol Technology 2nd ed. Hickey A, (Ed.). Marcel Dekker: New York (2004).
  • SMYTH HDC, MEJIA-MILLAN EA, HICKEY AJ: The effect of ethanol on solvency vapor pressure, and emitted droplet size of solution metered dose inhalers containing HFA 134a. Respiratory Drug Delivery VIII (2002) 2:735–738.
  • HARRIS J, GUPTA A, MYRDAL PB: Application of a new method for analysis of solubility in HFA-134a. Respiratory Drug Delivery IX (2004) 3:725–728.
  • JOHNSON KA: Interfacial phenomena and phase behaviour in metered-dose inhaler formulations. In: Inhalation Aerosols. Hickey AJ (Ed). Marcel Dekker: New York (19961:385–415.
  • PUREWAL TS: Formulation of metered dose inhalers. In: Metered dose inhaler technology Interpharm. Purewal TS, Grant DJW (Eds.). Buffalo Grove, 11 (1998).
  • ATKINS P: The development of new solution metered dose inhaler system. Paper presented at: Respiratory Drug Delivery II (1990) Keystone, CO.
  • SUAREZ S, HICKEY AJ: Drug properties affecting aerosol behaviour. Respir. Care (2000) 45(61:652–666.
  • TZOU TZ, PACHUTA RR, COY RB, SCHULTZ RK: Drug form selection in albuterol-containing metered-dose inhaler formulations and its impact on chemical and physical stability. J. Pharm. Sci. (1997) 86(12):1352–1357.
  • MICHAEL Y, SNOWDEN MJ, CHOWDHRY BZ, ASHURST IC, DAVIES-CUTTING CJ, RILEY T: Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system. Int. J. Pharm. (2001) 221(1-2):165–174.
  • MICHAEL Y, CHOWDHRY BZ, ASHURST IC, SNOWDEN MJ, DAVIES-CUTTING C, GRAYS: The physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments. Int. J. Pharm. (2000) 200(2):279–288.
  • STEFELY JS, BROWN B, HAMMERBECK DM, STEIN SW: Equiping the MDI for the 21st century by expanding its formulation options. Paper presented at: Respiratory Drug Delivery VIII (2002).
  • STEFELY JS, DUAN DC, BROWN BA, JOnVIAKOWSKI JP, RUBLE SA, SCHULTZ DW et al.: Surfactants designed for HFA-based MDIs. Proceeding of the 224th ACS National Meeting. Boston, MA, United States, 18–22 August, (2002) 2002:COLL–322.
  • ZHENG JY FULU M-Y, LEE DY, BARBER TE, ADJEI AL: Pulmonary peptide delivery: effect of taste-masking excipients on leuprolide suspension metered-dose inhalers. Pharm. Dev. TechnoL (2001) 6(4):521–530.
  • LAWRENCE MJ, REES GD: Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev. (2000) 45(1):89–121.
  • BUTZ N, PORTE C, COURRIER H, KRAFFT MP, VANDAMME TF: Reverse water-in-fluorocarbon emulsions for use in pressurized metered- dose inhalers containing hydrofluoroalkane propellants. Int. J. Pharm. (2002) 238(1-2):257–269.
  • DELLAMARY LA, TARARA TE, SMITH DJ et al.: Hollow porous particles in metered dose inhalers. Pharm. Res. (2000) 17(2):168–174.
  • WILLIAMS RO III, BARRON MK, JOSE ALONSO M, REMUNAN-LOPEZ C: Investigation of a pMDI system containing chitosan microspheres and P134a. Int. J. Pharm. (1998) 174(1-2):209–222.
  • DICKINSON PA, HOWELLS SW, KELLAWAYNovel nanoparticles forpulmonary drug administration. J. Drug Target. (2001) 9(4):295–302.
  • SOMMERVILLE ML, HICKEY AJ: Aerosol generation by metered-dose inhalers containing dimethyl ether/propane inverse microemulsions. AAPS Pharm. Sci.Tech. (2003) 4(4).
  • FASSBERG J, SEQUEIRA J, CHAUDHRY IA, KOPCHA M, INVENTORS: Non-chlorofluorocarbon aerosol formulation. (1995).
  • PUREWAL TS, GREENLEAF DJ, INVENTORS: Medical Aerosol Formulations. (1997).
  • BOWMAN PA, GREENLEAF D: Non-CFC metered dose inhalers: the patent landscape. Int. J. Pharm. (1999) 186(1):91–94.
  • LEACH C: Enhanced drug delivery through reformulating MDIs with HFA propellants-drug deposition and its effect on preclinical and clinical programs. Proceeding of the Respiratory Drug Delivery V Program. 1996:133–144.
  • CORREN J, TASHKIN DP: Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin. Ther. (2003) 25(3):776–798.
  • BARRY PW, O' The influence of inhaler selection on efficacy of asthma therapies. Adv. Drug. Del. Rev. (2003) 55(7):879–923.
  • DUBUS JC, RHEM R, DOLOVICH M: Delivery of HFA and CFC salbutamol from spacer devices used in infancy. Int. J. Pharm. (2001) 222 (1): 101–108.
  • JENKINS M: Clinical evaluation of CFC-free metered dose inhalers. J. Aerosol. Med. (1995) 8\(Suppl. 1):541–547.
  • KLEERUP EC, TASHKIN DP, CLINE AC, EKHOLM BP: Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulphate metered-dose inhaler in patients with asthma. Chest (1996) 109(3):702–707.
  • DAHL R, RINGDAL N, WARD SM, STAMPONE P, DONNELL D: Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate. Br. J. Clin. Pract. (1997) 51(1):11–15.
  • DOCKHORN RJ, WAGNER DE, BURGESS GL, HAFNER KB, LETOURNEAU K, COLICE GL et al.: Proventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin. Ann. Allergy Asthma ImmunoL (1997) 79(1):85–88.
  • MAESEN FP, GREEFHORST LP, SMEETS JJ, WALD FD, CORNELISSEN PJ: Therapeutic equivalence of a novel HFA 134a-containing metered-dose inhaler and the conventional CFC inhaler (Berodual) for the delivery of a fixed combination of fenoterol/ipratropium bromide. A randomized double-blind placebo-controlled crossover study in patients with asthma. Respiration (1997) 64(4):273–280.
  • NOGAMI-ITOH M, YAKUO I, HAMMERBECK DM, MILLER RL, TAKEYAMA K: The equivalent bronchodilator effects of salbutamol formulated in chlorofluorocarbon and hydrofluoroalkane-134a metered dose inhalers on the histamine-induced pulmonary response in dogs. Pharm. Res. (1997) 14(2):208–212.
  • BLUMENTHAL MN, CASALE TB, FINK JN, URYNIAK T, CASTY FE: Evaluation of a non-chlorofluorocarbon formulation of cromolyn sodium (Intal) metered-dose inhaler versus the chlorofluorocarbon formulation in the treatment of adult patients with asthma: a controlled trial. J. Allergy Clin. Immunol. (1998) 101(1 Pt 0:7–13.
  • DAVIES RJ, STAMPONE P, O'CONNOR BJ: Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorofluorocarbon beclomethasone dipropionate at approximately half the total daily dose. Respir. Med. (1998) 92(Suppl. A):23–31.
  • HERMANN R, RUUS P, SCHNEIDER E, De MEY C: Tolerability and in vivo performance of a novel freon-free metered dose inhaler for a fixed combinational product of reproterol and disodium cromoglycate. Arzneimittelforschung (1998) 48(6):663–667.
  • LEACH CL, DAVIDSON PJ, BOUDREAU RJ: Improved airway targeting with the CFC-free HFA-beclomethasone metered- dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. (1998) 12(6):1346–1353.
  • RAMSDELL JW, COLICE GL, EKHOLM BP, KLINGER NM: Cumulative dose response study comparing HFA-134a albuterol sulphate and conventional CFC albuterol in patients with asthma. Ann. Allergy Asthma ImmunoL (1998) 81(6):593–599.
  • SEALE JP, HARRISON LI: Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir. Med. (1998) 92(Suppl. A):9–15.
  • THOMPSON PJ, DAVIES RJ, YOUNG WF, GROSSMAN AB, DONNELL D: Safety of hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol. Respir. Med. (1998) 92(Suppl. A):33–39.
  • AYRES JG, SIMMONS JL, STAMPONE P: Acute safety of beclomethasone dipropionate in a new CFC-free propellant system in asthmatic patients. Respir. Med. (1999) 93(1):27–32.
  • BRONSKY E, EKHOLM BP, KLINGER NM, GOUGE GL: Switching patients with asthma from chlorofluorocarbon (CFC) albuterol to hydrofluoroalkane-134a (HFA) albuterol. J. Asthma (1999) 36(1):107–114.
  • BUSSE WW, BRAZINSKY S, JACOBSON K et al.: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant./ Allergy Clin. Immunol (1999) 104(6):1215–1222.
  • GOUGE GL, KLINGER NM, EKHOLM BP, DOCKHORN RJ: Proventil HFA prevents exercise-induced bronchoconstriction in children. J. Asthma (1999) 36(8):671–676.
  • DEMEDTS M, COHEN R, HAWKINSON R: Switch to non-CFC inhaled corticosteroids: a comparative efficacy study of HFA-BDP and CFC-BDP metered-dose inhalers. Int. J. Clin. Pract. (1999) 53(5):331–338.
  • FURUKAWA C, ATKINSON D, FORSTER TJ, NAZZARIO K, SIMPSON B, URYNIAK T et al.: Controlled trial of two formulations of cromolyn sodium in the treatment of asthmatic patients > or = 12 years of age. Intal Study Group. Chest (1999) 116(1):65–72.
  • GOLDIN JG, TASHKIN DP, KLEERUP EC et al.: Comparative effects of hydrofluoroalkane and chlorofluorocarbon beclomethasone dipropionate inhalation on small airways: assessment with functional helical thin-section computed tomography. J. Allergy Clin. Immunol (1999) 104(6):5258–5267.
  • GROSS G, THOMPSON PJ, CHERVINSKY P, VANDEN BURGT J: Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest (1999) 115(2):343–351.
  • HARRISON LI, SORIA I, CLINE AC, EKHOLM BP: Pharmacokinetic differences between chlorofluorocarbon and chlorofluorocarbon-free metered dose inhalers of beclomethasone dipropionate in adult asthmatics. J. Pharm. Pharmacol. (1999) 51(11):1235–1240.
  • JACOBSON K, CHERVINSKY P, NOONAN M, KANE RE, BANERJI D, URYNIAK T: Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. Ann. Allergy Asthma Immunol (1999) 83(4):327–333.
  • JUNIPER EF, BUIST AS: Health-related quality of life in moderate asthma: 400 um hydrofluoroalkane beclomethasone dipropionate versus 800 microg chlorofluorocarbon beclomethasone dipropionate. The Study Group. Chest (1999) 116(5):1297–1303.
  • MILANOWSKI J, QUALTROUGH J, PERRIN VL: Inhaled beclomethasone (BDP) with non-CFC propellant (HFA 134a) is equivalent to BDP-CFC for the treatment of asthma. Respir. Med. (1999) 93(4):245–251.
  • PARAMESWARAN KN, INMAN MD, EKHOLM BP et al.: Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist. Am. J. Respir. Crit. Care Med. (1999) 160(1):354–347.
  • RAMSDELL JW, KLINGER NM, EKHOLM BP, GOUGE GL: Safety of long-term treatment with HFA albuterol. Chest (1999) 115(0945–951.
  • AYRES JG, MILLAR AB, SYKES AP: Clinical efficacy and safety of fluticasone propionate 1 mg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with severe asthma. U.K. study group. Respir. Med. (2000) 94(Suppl. B):S42–S50.
  • BATEMAN ED, ADLER L, CHYREK-BOROWSKA S et al.: Inhaled triamcinolone acetonide HFA 450 mcg twice daily compared with beclomethasone dipropionate CFC 500 mcg twice daily in adults with moderate persistent asthma. Clin. Drug Inv. (2000) 20:9–17.
  • BAUMGARTEN CR, DOROW P, WEBER HH, GEBHARDT R, KETTNER J, SYKES AP: Equivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group. Respir. Med. (2000) 94(Suppl. B):517–521.
  • BOCCUZZI SJ, WOGEN J, ROEHM JB: Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Chn. Ther. (2000) 22(2):237–247.
  • FARMER IS, MIDDLE M, SAVIC J, PERRI VL, HERDMAN MJ: Therapeutic equivalence of inhaled beclomethasone dipropionate with CFC and non-CFC (HFA 134a) propellants both delivered via the Easibreathe inhaler for the treatment of paediatric asthma. Respir. Med. (2000) 94(1):57–63.
  • GOLDBERG J, BOHNING W, SCHMIDT P, FREUND E: Fenoterol hydrobromide delivered via HFA-MDI or CFC-MDI in patients with asthma: a safety and efficacy comparison. Respir. Med. (2000) 94(10):948–953.
  • HUCHON G, HOFBAUER P, CANNIZZARO G, IACONO P, WALD F: Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur. Respir. J. (2000) 15(4):663–669.
  • KUNKA R, ANDREWS S, PIMAZZONI M et al.: From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs. Respir. Med. (2000) 94(Suppl. B):S10–S16.
  • MACKIE AE, MCDOWALL JE, VENTRESCA P, BYE A. FALCOZ C, DALEY-YATES PT: Systemic exposure to fluticasone propionate administered via metered dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant. Clin. Pharmacokinet. (2000) 39\(Suppl. 1):17–22.
  • MAGNUSSEN H: Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG). Respir. Med. (2000) 94(0:549–555.
  • NELSON HS, KANE RE, PETILLO J, BANERJI D: Long-term safety of a non-chlorofluorocarbon-containing triamcinolone acetonide inhalation aerosol in patients with asthma. Azmacort HFA Study Group. J. Asthma (2000) 37(2):145–152.
  • PERRUCHOUD AP, LUNDBACK B, YIGLA M, SYKES AP: Clinical efficacy and safety of fluticasone propionate 1 mg per day administered via a HFA 134a pressurized metered dose inhaler to patients with moderate to severe asthma. International study group. Respir. Med. (2000) 94 (Suppl. B):535–541.
  • SHAPIRO G, BRONSKY E, MURRAY A, BARNHART F, VANDERMEER A, REISNER C: Clinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma. Arch. Pediatr. Adolesc. Med. (2000) 154(12):1219–1225.
  • TONNEL AB, BONS J, LEGENDRE M et al.: Clinical efficacy and safety of fluticasone propionate 250 um twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group. Respir. Med. (2000) 94(Suppl. B):S29–S34.
  • AUBIER M, WETTENGER R, GANS SJ: Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 um day(-1)) in patients with asthma. Respir. Med. (2001) 95(3):212–220.
  • CASALE TB, NELSON HS, CORREN J, NEWMAN K: Long-term safety of flunisolide hydrofluoroalkane metered-dose inhaler in adults and adolescents with asthma. Clin. Drug Inv. (2001) 21:755–764.
  • FIREMAN P, PRENNER BM, VINCKEN W, DEMEDTS M, MOL SJ, COHEN RM: Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann. Allergy Asthma Immunol (2001) 86(5):557–565.
  • LUMRY W, NOVECK R, WEINSTEIN S et al.: Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. Ann. Allergy Asthma Immunol (2001) 86(3):297–303.
  • NOLTING A. SISTA S, ABRAMOWITZ W: Flunisolide HFA versus flunisolide CFC: pharmacokinetic comparison in healthy volunteers. Biopharm. DrugDispos. (2001) 22(9):373–382.
  • TAYLOR J, KOTCH A, RICE K et al.: Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest (2001) 120(4):1253–1261.
  • WORTH H, MUIR JF, PIETERS WR: Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control. Respiration (2001) 68(5):517–526.
  • ANDERSON PB, LANGLEY SJ, MOONEY P, JONES J, AddlesTone R, ROSSETTI A et al.: Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics. J. Investig. Allergol Clin. Immunol (2002) 12(2):107–113.
  • BOUSQUET J, CANTINI L: Clinical studies in asthmatics with a new non-extra fine HFA formulation of beclometasone dipropionate (BDP Modulite). Respir. Med. (2002) 96(Suppl. D):517–527.
  • FOWLER SJ, ORR LC, SIMS EJ et al: Therapeutic ratio of hydrofluoroalkane and chlorofluorocarbon formulations of fluticasone propionate. Chest (2002) 122(2):618–623.
  • HAWKSWORTH RJ, SYKES AP, FARIS M, MANT T, LEE TH: Albuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction. Ann. Allergy Asthma Immunol (2002) 88(5):473–477.
  • JUNIPER EF, PRICE DB, STAMPONE PA, CREEMERS JP, MOL SJ, FIREMAN P: Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest (2002) 121(6):1824–1832.
  • LANGLEY SJ, SYKES AP, BATTY EP, MASTERSON CM, WOODCOCK k A comparison of the efficacy and tolerability of single doses of HFA 134a albuterol and CFC albuterol in mild-to-moderate asthmatic patients. Ann. Allergy Asthma Immunol (2002) 88(5):488–493.
  • LEACH CL, DAVIDSON PJ, HASSELQUIST BE, BOUDREAU RJ: Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest (2002) 122(2):510–516.
  • NOLTING A, SISTA S, ABRAMOWITZ W: Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide. J. Pharm. Sci. (2002) 91(2):424–432.
  • PRICED, HAUGHNEY J, DUERDEN M, NICHOLLS C, MOSELEY C: The cost effectiveness of chlorofluorocarbon-free beclomethasone dipropionate in the treatment of chronic asthma: a cost model based on a 1-year pragmatic, randomised clinical study. Pharmacoeconomics (2002) 20(10):653–664.
  • SZEFLER SJ, WARNER J, STAAB D, WAHN U, LE BOURGEOIS M, VAN ESSEN-ZANDVLIET EE et al.: Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open- label, randomized trial. J. Allergy Clin. Immunol (2002) 110(1):45–50.
  • JOGUPARTHI V BREEN P, COMPADRE C et al.: Effect of Propellant on the Pharmacokinetics and Pharmacodynamics of Inhaled Albuterol in Asthmatic Subjects. J. Aerosol Med. (2003) 16(1):47–53.
  • BRAZINSKY SA, LAPIDUS RJ, WEISS LA, GHAFOURI M, FAGAN NM, WITEK TJ: One-year evaluation of the safety and efficacy of ipratropium bromide HFA and CFC inhalation aerosols in patients with chronic obstructive pulmonary disease. Clin. Drug Inv. (2003) 23(3):181–191.
  • GRZELEWSKA-RZYMOWSKA I, MALOLEPSZY J, De MOLINA M, SLADEK K, ZARKOVICE J, SIERGIEJKO Z: Equivalent asthma control and systemic safety of inhaled budesonide delivered via HFA-134a or CFC propellant in a broad range of doses. Respir. Med. (2003) 97 (Suppl. D):S10–519.
  • LYTTLE B, GILLES J, PANOV M, EMERYK A, WIXON C: Fluticasone propionate 100 microg bid using a non-CFC propellant, HFA 134a, in asthmatic children. Can. Respir. J. (2003) 10(2):103–109.
  • HOLZ O, ZUHLKE I, EINHAUS M et al.: Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- versus CFC-driven aerosols. Pulm. Pharmacol. Therapeutics (2004) 17(4):233–238.
  • VAN NOORD JA, LILL H, DIAZ TC, GREEFHORST AP, DAVIES P: Clinical equivalence of a salmeterol/fluticasone propionate combination product (50/ 500mg) delivered via a chlorofluorocarbon-free metered-dose inhaler with the diskus in patients with moderate to severe asthma. Clin. Drug Inv. (2001) 21(4):243–255.
  • ARGENTI D, SHAH B, HEALD D: A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. J. Clin. Pharmacol (2000) 40(5):516–526.
  • GUSTAFSSON P, KALLMAN S, -WHITEHEAD PJ: Clinical equivalence between salbutamol hydrofluoroalkane pMDI and salbutamol Turbuhaler at the same cumulative microgram doses in paediatric patients. Respir. Med. (2002) 96(11):957–959.
  • AFFRIME MB, CUSS F, PADHI D et al.: Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J. Clin. Pharmacol (2000) 40(11):1227–1236.
  • LIPWORTH BJ, CLARKE DJ: Lung delivery of salbutamol by dry powder inhaler (Turbuhaler) and small volume antistatic metal spacer (Airomir CFC-free MDI plus NebuChamber). Eur. Respir. (1997) 10(8):1820–1823.
  • SZEFLER SJ, MARTIN RJ, KING TS et al.: Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. (2002) 109(3):410–418.
  • ADLER LM, ANAND C, WRIGHT FGDL et al.: Efficacy and tolerability of beclomethasone dipropionate delivered by a novel multidose dry powder inhaler (Clickhaler) versus a metered-dose inhaler in children with asthma. Current Therapeutic Research (2001) 62(11):758–769.
  • NATHAN RA, NAYAK AS, GRAFT DF et al.: Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Ann. Allergy Asthma Immunol (2001) 86(2):203–210.
  • AFFRIME MB, KOSOGLOU T, THONOOR CM, FLANNERY BE, HERRON JM: Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Chest (2000) 118(6):1538–1546.
  • NELSON H, KEMP JP, BIELER S, VAUGHAN LM, HILL MR: Comparative efficacy and safety of albuterol sulphate Spiros inhaler and albuterol metered-dose inhaler in asthma. Chest (1999) 115(2):329–335.
  • CHEGE JK, PARRY-BILLINGS M, CHRYSTYN H: Relative bioavailability of salbutamol to the lung following inhalation via two versions of a novel dry powder inhaler (Clickhaler) and a standard pressurized metered dose inhaler (Ventolin). Pharm. Pharmacol. Com. (1998) 4(2):107–109.
  • HINDLE M, PEERS EM, PARRY-BILLINGS M, CHRYSTYN H: Relative bioavailability of salbutamol to the lung following inhalation via a novel dry powder inhaler and a standard metered dose inhaler. Br. J. Clin. Pharmacol (1997) 43(3):336–338.
  • VON BERG A, JEENA P, SOEMANTRI PA et al.: Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler versus a conventional metered dose inhaler plus spacer in children with asthma. Pediatr. Pulmonol. (2004) 37(3):264–272.
  • VINCKEN W, BANTJE T, MIDDLE MV GERKEN F, MOONEN D: Long-term efficacy and safety of ipratropium bromide plus fenoterol via Respimat soft Mist Inhaler (SMI) versus a pressurized metered-dose inhaler in asthma. Clin. Drug Inv. (2004) 24(1):17–28.
  • VINCKEN W, DEWBERRY H, MOONEN D: Fenoterol delivery by respimat soft mist inhaler versus CFC metered dose inhaler: cumulative dose-response study in asthma patients. J. Asthma (2003) 40(6):721–730.
  • GOLDBERG J, FREUND E, BECKERS B, HINZMANN R: Improved delivery of fenoterol plus ipratropium bromide using Respimat compared with a conventional metered dose inhaler. Eur. Respir. J. (2001) 17(2):225–232.
  • KILFEATHER SA, PONITZ HH, BECK E et al.: Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. Respir. Med. (2004) 98(5):387–397.
  • EVERARD ML: CFC transition: the Emperor's new clothes. Each class of drug deserves a delivery system that meets its own requirements. Thorax (2000) 55:811–814.
  • RAM FS, BROCKLEBANK DM, WHITE J, WRIGHT JP, JONES PW: Pressurised metered dose inhalers versus all other hand-held inhaler devices to deliver beta-2 agonist bronchodilators for non-acute asthma. Cochrane Database Syst. Rev. (2002) 1.
  • BROCKLEBANK D, RAM F, WRIGHT J, BARRY P, GATES C, DAVIES L et al: Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assessment (2001) 5(26):1–149.
  • HARTUNG TK, ALLBUTT H, DEWAR M, INNES JA, CROMPTON GK: Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think? Respiration (2002) 69(4):314–319.
  • MOLINA MJ, ROWLAND FS: Stratospheric sink for chlorofluoromethane: chlorine atom catalysed destruction of ozone. Nature (1974) 274:810–812.
  • FORTE R, Jr., DIBBLE C: The role of international environmental agreements in metered-dose inhaler technology changes. J. Allergy Clin. Immunol. (1999) 104(6):5217–5220.
  • COLE CH: Special Problems in Aerosol Delivery: Neonatal and paediatric considerations. Respir. Care (2000) 45(0:646–651.
  • EVERARD ML: Inhalation Therapy for Infants. Adv. Drug Del. Rev. (2003) 55:869–878.
  • HELMS PJ, CHRISTIE G: Prospects for preventing asthma. Archives Dis. Childhood (1999) 80(5):401–404.
  • HUELS G, MUELLER M, VON BREDOW C et al.: Long term efficacy of aerosolized amiloride in paediatric patients with cystic fibrosis. Proceedings of the 24th European Cyctic Fibrosis Conference. Genoa, Italy, 20–23 June, (2002) 2002:251–253.
  • ROSENFELD M, GIBSON R, MCNAIVIARA S, EMERSON J, MCCOY KS, SHELL R et al.: Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J. Pediatr. (2001) 139(4):572–577.
  • ENGLUND JA, PIEDRA PA, WHIMBEY E: Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients. Am. J. Med. (1997) 102(3A):61–70.
  • COLE CH, COLTON T, SHAH BL et al.: Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl. J. Med. (1999) 340(13): 1005–1010.
  • GONDA I: Targeting by Deposition. In: Pharmaceutical Aerosol Inhalation Technology 2nd ed. Hickey AJ, (Ed).Marcel Dekker: New York (2004):65–88.
  • DOLOVICH M: Aerosol delivery to children: what to use, how to choose. Paediatr. Pulmonol. (1999) 18:79–82.
  • DEVADASON SG, EVERARD ML, MACEARLAN G et al.: Lung deposition from the Turbuhaler in children with cystic fibrosis. Eur. Respir. J. (1997) 10(9): 2023–2028.
  • WILDHABER JH, DEVADASON SG, WILSON JM et al.: Lung deposition of budesonide from Turbuhaler in asthmatic children. Eur. j Pediatr. (1998) 157(12):1017–1022.
  • WILDHABER JH, DEVADASON SG, HAYDEN MJ, EBER E, SUMMERS QA, LESOUEF PN: Aerosol delivery to wheezy infants: a comparison between a nebulizer and two small volume spacers. Paediatr. PulmonoL (1997) 23(3):212–216.
  • IQBAL S, RITSON S, PRINCE I, DENYER J, EVERARD MARK L: Drug delivery and adherence in young children. Paediatr. PulmonoL (2004) 37(4):311–317.
  • AMIRAV I, MANSOUR Y, MANDLEBERG A. BAR-IIAN I, NEWHOUSE M: Redesigned Face Mask Improves "Real Life" Aerosol Delivery for Nebuchamber. Pediam. Pulmonol. (2004) 37:172–177.
  • AMIRAV I, NEWHOUSE MT: Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Paediatrics (2001) 108(2):389–394.
  • JANSSENS HM, DEVADASON SG, HOP WC, LESOUEF PN, DE JONGSTE JC, TIDDENS HA: Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. Eur. Res. J. (1999) 13(4):787–791.
  • The Bottleneck. Sci. Am. 2002 Feburary.
  • AMES SA, GLEESON CD, KIRKPATRICK P: Omalizumab. Nat Rev. Drug Discov. (2004) 3(3):199–200.
  • CROWDER TM: Vibration Technology for Active Dry-Powder Inhalers. Pharm.TechnoL (2004):52–61.

Websites

  • http://www.fda.gov/cder/guidance/ index.htm FDA. Guidance for Industry: Integration of dose-counting mechanisms into MDI drug products: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). (2003).
  • http://www.fluorocarbons.org
  • http://www.gsk.com

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.